Vivimed Labs files for Pre-pack Insolvency Resolution Process with Rs. 512 Crore default
Vivimed Labs Limited filed an application for Pre-pack Insolvency Resolution Process on February 12, 2026. The company reported a default amount of ₹512.53 crore as of January 31, 2026. This action is taken under section 54A of the IBC Act.
Filing for insolvency resolution is a critical event that can significantly impact the company's operations, financial standing, and shareholder value.
The company has filed for an insolvency resolution process, indicating severe financial distress, which is a negative development.
Vivimed Labs Limited has filed an application for the initiation of a Pre-pack Insolvency Resolution Process (PPIRP) with the Insolvency and Bankruptcy Board of India (NCLT Bengaluru Bench) on February 12, 2026. This follows previous intimations dated November 13, 2025, and January 10, 2025.
As of January 31, 2026, the amount in default stands at ₹512,53,06,756 (Five hundred twelve crores, fifty-three lakhs, six thousand, seven hundred and fifty-six rupees).
The company has submitted the application under section 54A of the IBC Act. This announcement is made in accordance with Regulation 30 of SEBI (LODR) 2015.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under corporate insolvency resolution process. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.